BACKGROUND: Variation at the human mu-opioid receptor has been associated with alcohol abuse. The A118G (N40D) polymorphism in humans is functionally mimicked by the C77G (P26R) polymorphism in rhesus monkeys; both show similar in vitro influences on ligand binding and in vivo correlations with physiological measures as well as behavioral measures including predilection towards alcohol consumption. Naltrexone, an antagonist at the receptor, has been used to treat alcoholism in humans and has been reported to show differences in effectiveness depending on genotype. METHODS: Here we describe a study in which we a priori selected rhesus monkeys based on genotype at the OPRM1 C77G single nucleotide polymorphism, trained them to self-administer alcohol, and assessed naltrexone responsiveness. RESULTS: Alcohol intake in rhesus monkeys varied with genotype across a range of alcohol concentrations (0.5-4%, w/v) such that animals with the G/G genotype drank consistently more alcohol than those animals with the C/C genotype. Additionally, naltrexone attenuated alcohol drinking in a dose- and genotype-dependent manner. Animals harboring the G/G genotype were more sensitive to the effects of naltrexone and showed greater reductions in alcohol consumption at lower naltrexone doses compared to animals with a C/G or C/C genotype. CONCLUSIONS: This preliminary study demonstrates a pharmacogenomic response to naltrexone in rhesus monkeys that parallels that seen in humans. This finding provides a basis for developing a pharmacogenetic animal model for naltrexone effect that can expand further our understanding of the causes and treatments of alcohol use disorders. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND: Variation at the humanmu-opioid receptor has been associated with alcohol abuse. The A118G (N40D) polymorphism in humans is functionally mimicked by the C77G (P26R) polymorphism in rhesus monkeys; both show similar in vitro influences on ligand binding and in vivo correlations with physiological measures as well as behavioral measures including predilection towards alcohol consumption. Naltrexone, an antagonist at the receptor, has been used to treat alcoholism in humans and has been reported to show differences in effectiveness depending on genotype. METHODS: Here we describe a study in which we a priori selected rhesus monkeys based on genotype at the OPRM1C77G single nucleotide polymorphism, trained them to self-administer alcohol, and assessed naltrexone responsiveness. RESULTS:Alcohol intake in rhesus monkeys varied with genotype across a range of alcohol concentrations (0.5-4%, w/v) such that animals with the G/G genotype drank consistently more alcohol than those animals with the C/C genotype. Additionally, naltrexone attenuated alcohol drinking in a dose- and genotype-dependent manner. Animals harboring the G/G genotype were more sensitive to the effects of naltrexone and showed greater reductions in alcohol consumption at lower naltrexone doses compared to animals with a C/G or C/C genotype. CONCLUSIONS: This preliminary study demonstrates a pharmacogenomic response to naltrexone in rhesus monkeys that parallels that seen in humans. This finding provides a basis for developing a pharmacogenetic animal model for naltrexone effect that can expand further our understanding of the causes and treatments of alcohol use disorders. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: Jennifer M Mitchell; Howard L Fields; Raymond L White; Thomas M Meadoff; Geoff Joslyn; Michael C Rowbotham Journal: J Clin Psychopharmacol Date: 2007-02 Impact factor: 3.153
Authors: M Smolka; T Sander; L G Schmidt; J Samochowiec; H Rommelspacher; N Gscheidel; B Wendel; M R Hoehe Journal: Psychoneuroendocrinology Date: 1999-08 Impact factor: 4.905
Authors: Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig Journal: Neuropsychopharmacology Date: 2005-02 Impact factor: 7.853
Authors: C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205
Authors: David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien Journal: Neuropsychopharmacology Date: 2003-06-18 Impact factor: 7.853
Authors: Christina S Barr; Scott A Chen; Melanie L Schwandt; Stephen G Lindell; Hui Sun; Stephen J Suomi; Markus Heilig Journal: Biol Psychiatry Date: 2010-01-01 Impact factor: 13.382
Authors: Lara A Ray; Christina S Barr; Julie A Blendy; David Oslin; David Goldman; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2011-09-06 Impact factor: 3.455
Authors: Eileen K Sawyer; Casey Moran; Madelynn H Sirbu; Melissa Szafir; Michael Van Linn; Ojas Namjoshi; V V N Phani Babu Tiruveedhula; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2013-12-13 Impact factor: 3.455
Authors: J Rogers; M Raveendran; G L Fawcett; A S Fox; S E Shelton; J A Oler; J Cheverud; D M Muzny; R A Gibbs; R J Davidson; N H Kalin Journal: Mol Psychiatry Date: 2012-11-13 Impact factor: 15.992